Welcome to our dedicated page for Aadi Bioscience news (Ticker: AADI), a resource for investors and traders seeking the latest updates and insights on Aadi Bioscience stock.
Aadi Bioscience Inc (NASDAQ: AADI) is a clinical-stage biopharmaceutical company pioneering precision oncology therapies for rare cancers driven by mTOR pathway alterations. This page serves as the definitive source for verified news, press releases, and corporate updates directly from the company.
Investors and researchers will find timely information on FYARRO® developments, clinical trial progress, and strategic partnerships. Our curated collection includes earnings reports, regulatory filings, and scientific presentations – all essential for understanding AADI's position in targeted cancer treatment.
Key updates cover three areas: clinical research (trial results, FDA communications), business operations (partnerships, executive appointments), and therapeutic advancements (new indications, technology innovations). Each piece is sourced to ensure accuracy and relevance for stakeholders.
Bookmark this page for efficient tracking of AADI's progress in developing nanoparticle albumin-bound therapies. Check back regularly for objective updates on their mission to address unmet needs in genomic alteration-driven cancers.
Aadi Bioscience, a biopharmaceutical company, announced the acceptance of abstracts for the 2023 ASCO Annual Meeting from June 2-6 in Chicago. The presentations will highlight updates from the PRECISION 1 Phase 2 study and combination data from an ongoing trial involving nab-sirolimus and pazopanib. Key poster details include:
- Title: Phase 2 multicenter trial of nab-sirolimus for patients with TSC1 or TSC2 gene alterations. Date: June 3, 2023, 8:00 AM-11:00 AM.
- Title: Phase I study of nab-sirolimus with pazopanib in advanced soft tissue sarcoma. Date: June 3, 2023, 1:15 PM-4:15 PM.
Aadi's FDA-approved product, FYARRO, targets advanced PEComa. The company aims to advance precision therapies for cancers driven by mTOR pathway alterations.
Aadi Bioscience (NASDAQ: AADI) announced three poster presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting, which runs from April 14-19 in Orlando, FL. The presentations include updates on the ongoing PRECISION 1 trial, which studies nab-sirolimus in patients with TSC1 or TSC2 gene alterations. Key highlights feature the anti-tumor efficacy of nab-sirolimus combined with KRAS inhibitors in xenograft models, and a biomarker analysis from the AMPECT trial correlating responses to nab-sirolimus with TSC1 and TSC2 mutations. The sessions are scheduled for April 17 and 18, showcasing the advancements in precision therapies for genetically defined cancers, reinforcing Aadi's commitment to innovative treatment solutions.
Aadi Bioscience, Inc. (NASDAQ: AADI) announced its participation at the American Association for Cancer Research (AACR) Annual Meeting 2023, scheduled from April 14-19, 2023 in Orlando, FL. The company will present three posters focusing on innovative cancer therapies linked to mTOR pathway genes. Key presentations include:
- Title: "Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with inactivating alterations in TSC1 or TSC2 (PRECISION I)" on April 17, 2023.
- Title: "Synergistic anti-tumor activity of nab-sirolimus in combination with KRAS inhibitors" on April 18, 2023.
- Title: "Biomarker analysis from AMPECT" on April 19, 2023.
Post-presentation, materials will be available on Aadi's investor relations page.
Aadi Bioscience (AADI) reported total revenue of $15.2 million from FYARRO® sales in FY 2022. The fourth quarter generated $5.2 million, showing a 23% sequential growth. The company announced a net loss of $60.5 million for 2022, improved from $110.1 million in 2021. A $72.5 million financing closed in Q4 extended the cash runway to 2025. The PRECISION 1 trial is progressing, with preliminary data expected in Q2 2023. Aadi also signed a collaboration with Mirati Therapeutics for a Phase 1/2 trial starting in Q2 2023.
Aadi Bioscience, Inc. (NASDAQ: AADI) has appointed Dr. Mohammad Hirmand to its Board of Directors. Dr. Hirmand brings over 20 years of experience in biotechnology and previously served as EVP and CMO at Turning Point Therapeutics, acquired by Bristol Myers Squibb for $4.1 billion in August 2022. His expertise in oncology and previous roles at Medivation and Peloton Therapeutics are expected to enhance Aadi's strategic direction, especially in advancing its FYARRO therapy beyond its current use for PEComa. The company is also conducting the PRECISION-1 trial for nab-sirolimus in mTOR-driven solid tumors.
Aadi Bioscience (NASDAQ: AADI) presented clinical data from its PRECISION 1 and AMPECT trials at the Society of Gynecological Oncology Annual Meeting 2023 in Tampa, FL, held from March 25-28, 2023. The company showcased two posters highlighting significant findings related to nab-sirolimus for treating solid tumors with mTOR pathway gene alterations. The PRECISION I trial focuses on a tumor-agnostic approach for patients with TSC1 or TSC2 alterations, while the AMPECT trial provides insights into responses in patients with primary uterine PEComa. Aadi continues its commitment to developing precision therapies for genetically defined cancers.
Aadi Bioscience, a biopharmaceutical firm, will host a conference call on March 28, 2023, at 8:30 AM EDT to discuss its fourth quarter and full-year 2022 financial results and corporate updates. The call will be accessible via live webcast on their website. Aadi specializes in precision therapies for genetically-defined cancers, notably receiving FDA approval for FYARRO® to treat advanced malignant perivascular epithelioid cell tumors. Additionally, they are initiating the PRECISION 1 trial targeting solid tumors with specific genetic alterations.
Aadi Bioscience, Inc. (NASDAQ: AADI) announced the resignation of CEO Brendan Delaney due to personal reasons, with CFO Scott Giacobello appointed as Interim CEO. Neil Desai, the founder and former CEO, will assist during the transition. The board is currently searching for a permanent CEO. Aadi continues to advance the development of FYARRO nab-sirolimus, targeting solid tumors with TSC1 and TSC2 mutations while supporting patients with PEComa. Giacobello highlighted a strong financial position and a commitment to delivering solutions for unmet needs in oncology.
FAQ
What is the current stock price of Aadi Bioscience (AADI)?
What is the market cap of Aadi Bioscience (AADI)?
